Volume 29 Issue 10
Oct.  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(10): 1757-1760
CHEN Hong, KUANG Hongying, ZHOU Ying, LIN Wenhua, LIN Chao, CHEN Qionghua. Research progress of microRNA-200a/b/c/-429 family in ovarian cancer[J]. Chinese Journal of General Practice, 2025, 23(10): 1757-1760. doi: 10.16766/j.cnki.issn.1674-4152.004222
Citation: CHEN Hong, KUANG Hongying, ZHOU Ying, LIN Wenhua, LIN Chao, CHEN Qionghua. Research progress of microRNA-200a/b/c/-429 family in ovarian cancer[J]. Chinese Journal of General Practice, 2025, 23(10): 1757-1760. doi: 10.16766/j.cnki.issn.1674-4152.004222
shu

Research progress of microRNA-200a/b/c/-429 family in ovarian cancer

doi: 10.16766/j.cnki.issn.1674-4152.004222
  • 1.

    Department of Obstetrics and Gynecology, the First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361003, China

Funds:

 2022J05310

  • Received Date: 2024-04-07
    Abstract
  • This article explores the functional mechanisms of the miR-200 family in tumorigenesis, specifically focusing on the contributions of miR-200a/b/c/-429 to cancer initiation and progression. The miR-200 family plays a crucial role in tumor biology by influencing growth, spread, invasion, and chemotherapy resistance. They are vital in the epithelial-to-mesenchymal transition, which aids tumor spread, and also regulate tumor cell survival and growth, contributing to cancer dissemination. The miR-200 family plays a key role in tumor cell invasion and metastasis and holds potential as diagnostic and prognostic markers for ovarian cancer. Future research should investigate the mechanisms in various tumors and apply these insights for early diagnosis and treatment strategies. Studying the miR-200 family in tumors can provide insights into their functions, improving treatment options and enhancing survival with significant scientific and clinical benefits.

     

    • FullText(HTML)
  • loading
    • References(44)
  • [1]
    HILL M, TRAN N. miRNA interplay: mechanisms and consequences in cancer[J]. Dis Model Mech, 2021, 14(4): dmm047662. DOI: 10.1242/dmm.047662.
    [2]
    MEHTEROV N. Role of microRNAs in cancer development and treatment[J]. Int J Mol Sci, 2023, 24(13): 11058. DOI: 10.3390/ijms241311058.
    [3]
    HO P T B, CLARK I M, LE L T T. MicroRNA-based diagnosis and therapy[J]. Int J Mol Sci, 2022, 23(13): 7167. DOI: 10.3390/ijms23137167.
    [4]
    ANDERSEN G B, TOST J. Circulating miRNAs as biomarker in cancer[J]. Recent Results Cancer Res, 2020, 215: 277-298.
    [5]
    HUSSEN B M, HIDAYAT H J, SALIHI A, et al. MicroRNA: a signature for cancer progression[J]. Biomed Pharmacother, 2021, 138: 111528. DOI: 10.1016/j.biopha.2021.111528.
    [6]
    FERRAGUT CARDOSO A P, BANERJEE M, NAIL A N, et al. miRNA dysregulation is an emerging modulator of genomic instability[J]. Semin Cancer Biol, 2021, 76: 120-131. doi: 10.1016/j.semcancer.2021.05.004
    [7]
    AKBARZADEH M, MIHANFAR A, AKBARZADEH S, et al. Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer[J]. Life Sci, 2021, 285: 119984. DOI: 10.1016/j.lfs.2021.119984.
    [8]
    SAFA A, ABAK A, SHOOREI H, et al. MicroRNAs as regulators of ERK/MAPK pathway: a comprehensive review[J]. Biomed Pharmacother, 2020, 132: 110853. DOI: 10.1016/j.biopha.2020.110853.
    [9]
    HE B, ZHAO Z, CAI Q, et al. miRNA-based biomarkers, therapies, and resistance in cancer[J]. Int J Biol Sci, 2020, 16(14): 2628-2647. doi: 10.7150/ijbs.47203
    [10]
    KLICKA K, GRZYWA T M, MIELNICZUK A, et al. The role of miR-200 family in the regulation of hallmarks of cancer[J]. Front Oncol, 2022, 12: 965231. DOI: 10.3389/fonc.2022.965231.
    [11]
    JO H, SHIM K, JEOUNG D. Potential of the miR-200 Family as a target for developing anti-cancer therapeutics[J]. Int J Mol Sci, 2022, 23(11): 5881. DOI: 10.3390/ijms23115881.
    [12]
    CAVALLARI I, CICCARESE F, SHAROVA E, et al. The miR-200 family of micrornas: fine tuners of epithelial-mesenchymal transition and circulating cancer biomarkers[J]. Cancers (Basel), 2021, 13(23): 5874. DOI: 10.3390/cancers13235874.
    [13]
    BUSTOS M A, ONO S, MARZESE D M, et al. MiR-200a regulates CDK4/6 inhibitor effect by targeting CDK6 in metastatic melanoma[J]. J Invest Dermatol, 2017, 137(9): 1955-1964. doi: 10.1016/j.jid.2017.03.039
    [14]
    HOU X, YANG L, JIANG X, et al. Role of microRNA-141-3p in the progression and metastasis of hepatocellular carcinoma cell[J]. Int J Biol Macromol, 2019, 128: 331-339. doi: 10.1016/j.ijbiomac.2019.01.144
    [15]
    TAN T, XU X H, LU X H, et al. MiRNA-200a-3p suppresses the proliferation, migration and invasion of non-small cell lung cancer through targeting IRS2[J]. Eur Rev Med Pharmacol Sci, 2020, 24(2): 712-720.
    [16]
    MU J W, ZHOU X Y, WANG Q J, et al. MicroRNA-141-3p promoted the progression of nasopharyngeal carcinoma through targeting DLC1[J]. Eur Rev Med Pharmacol Sci, 2020, 24(21): 11105-11113.
    [17]
    李栗扬, 徐鹏, 王蓓蒂, 等. MicroRNA-429在妇科恶性肿瘤中的研究进展[J]. 中华全科医学, 2021, 19(6): 1013-1016, 1034. doi: 10.16766/j.cnki.issn.1674-4152.001973

    LI L Y, XU P, WANG B D, et al. Research Progress of MicroRNA-429 in Gynecological Malignancies[J]. Chinese Journal of General Practice, 2021, 19(6): 1013-1016, 1034. doi: 10.16766/j.cnki.issn.1674-4152.001973
    [18]
    陈恩利, 楼俊晓, 王镇, 等. lncRNA GIHCG通过调节miR-429在原发性肝癌发生发展中的作用[J]. 中华全科医学, 2019, 17(5): 779-783. doi: 10.16766/j.cnki.issn.1674-4152.000790

    CHEN E L, LOU J X, WANG Z, et al. lncRNA GIHCG plays a role in the occurrence and development of primary liver cancer by regulating miR-429[J]. Chinese Journal of General Practice, 2019, 17(5): 779-783. doi: 10.16766/j.cnki.issn.1674-4152.000790
    [19]
    PAN G, LIU Y, SHANG L, et al. EMT-associated microRNAs and their roles in cancer stemness and drug resistance[J]. Cancer Commun (Lond), 2021, 41(3): 199-217. doi: 10.1002/cac2.12138
    [20]
    YU L, CAO C, LI X, et al. Complete loss of miR-200 family induces EMT associated cellular senescence in gastric cancer[J]. Oncogene, 2022, 41(1): 26-36. doi: 10.1038/s41388-021-02067-y
    [21]
    FUNATO N, YANAGISAWA H. TBX1 targets the miR-200-ZEB2 axis to induce epithelial differentiation and inhibit stem cell properties[J]. Sci Rep, 2022, 12(1): 20188. DOI: 10.1038/s41598-022-24604-9.
    [22]
    GOLLAVILLI P N, PARMA B, SIDDIQUI A, et al. The role of miR-200b/c in balancing EMT and proliferation revealed by an activity reporter[J]. Oncogene, 2021, 40(12): 2309-2322. doi: 10.1038/s41388-021-01708-6
    [23]
    CHONG Z X, HO W Y, YEAP S K. Deciphering the roles of non-coding RNAs in liposarcoma development: challenges and opportunities for translational therapeutic advances[J]. Noncoding RNA Res, 2025, 11: 73-90. doi: 10.1016/j.ncrna.2024.11.005
    [24]
    NILSEN A, HILLESTAD T, SKINGEN V E, et al. miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer[J]. Mol Oncol, 2022, 16(6): 1402-1419. doi: 10.1002/1878-0261.13184
    [25]
    CHOI P W, BAHRAMPOUR A, NG S K, et al. Characterization of miR-200 family members as blood biomarkers for human and laying hen ovarian cancer[J]. Sci Rep, 2020, 10(1): 20071. DOI: 10.1038/s41598-020-77068-0.
    [26]
    THI CHUNG DUONG T, NGUYEN T H N, THI NGOC NGUYEN T, et al. Diagnostic and prognostic value of miR-200 family in breast cancer: a meta-analysis and systematic review[J]. Cancer Epidemiol, 2022, 77: 102097. DOI: 10.1016/j.canep.2022.102097.
    [27]
    RAMIREZ-MOYA J, BAKER A R, SLACK F J, et al. ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity[J]. Oncogene, 2020, 39(18): 3738-3753. doi: 10.1038/s41388-020-1248-x
    [28]
    GHEIDARI F, AREFIAN E, SAADATPOUR F, et al. The miR-429 suppresses proliferation and migration in glioblastoma cells and induces cell-cycle arrest and apoptosis via modulating several target genes of ERBB signaling pathway[J]. Mol Biol Rep, 2022, 49(12): 11855-11866. doi: 10.1007/s11033-022-07903-2
    [29]
    NOVIKOV N M, ZOLOTARYOVA S Y, GAUTREAU A M, et al. Mutational drivers of cancer cell migration and invasion[J]. Br J Cancer, 2021, 124(1): 102-114. doi: 10.1038/s41416-020-01149-0
    [30]
    UHAN S, HAUPTMAN N. Metastatic EMT phenotype is governed by microrna-200-mediated competing endogenous RNA networks[J]. Cells, 2021, 11(1): 73. DOI: 10.3390/cells11010073.
    [31]
    ALAM F, MEZHAL F, EL HASASNA H, et al. The role of p53-microRNA 200-Moesin axis in invasion and drug resistance of breast cancer cells[J]. Tumour Biol, 2017, 39(9): 1010428317714634. DOI: 10.1177/1010428317714634.
    [32]
    LI D, WANG H, SONG H, et al. The microRNAs miR-200b-3p and miR-429-5p target the LIMK1/CFL1 pathway to inhibit growth and motility of breast cancer cells[J]. Oncotarget, 2017, 8(49): 85276-85289. doi: 10.18632/oncotarget.19205
    [33]
    CHEON I, LEE S, OH S, et al. miR-200-mediated inactivation of cancer-associated fibroblasts via targeting of NRP2-VEGFR signaling attenuates lung cancer invasion and metastasis[J]. Mol Ther Nucleic Acids, 2024, 35(2): 102194. DOI: 10.1016/j.omtn.2024.102194.
    [34]
    JING Y, LIANG W, LIU J, et al. Autophagy-mediating microRNAs in cancer chemoresistance[J]. Cell Biol Toxicol, 2020, 36(6): 517-536. doi: 10.1007/s10565-020-09553-1
    [35]
    YU S J, YANG L, HONG Q, et al. MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer[J]. BMC Cancer, 2018, 18(1): 1-11. doi: 10.1186/s12885-017-3892-2
    [36]
    PENG F, HE R, LIU Y, et al. MiR-200b-3p elevates 5-FU sensitivity in cholangiocarcinoma cells via autophagy inhibition by targeting KLF4[J]. Noncoding RNA Res, 2024, 9(4): 1098-1110. doi: 10.1016/j.ncrna.2024.06.004
    [37]
    FRISK N L S, SORENSEN A E, PEDERSEN O B V, et al. Circulating microRNAs for early diagnosis of ovarian cancer: a systematic review and meta-analysis[J]. Biomolecules, 2023, 13(5): 871. doi: 10.3390/biom13050871
    [38]
    FERNEZA S, FETSYCH M, SHULIAK R, et al. Clinical significance of microRNA-200 and let-7 families expression assessment in patients with ovarian cancer[J]. Ecancermedicalscience, 2021, 15: 1249. DOI: 10.3332/ecancer.2021.1249.
    [39]
    CITTELLY D M, DIMITROVA I, HOWE E N, et al. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel[J]. Mol Cancer Ther, 2012, 11(12): 2556-2565. doi: 10.1158/1535-7163.MCT-12-0463
    [40]
    LIU J, ZHANG X, HUANG Y, et al. miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases[J]. Oncol Lett, 2019, 17(2): 1453-1460.
    [41]
    CHEN H, XIA B, LIU T, et al. KIAA0101, a target gene of miR-429, enhances migration and chemoresistance of epithelial ovarian cancer cells[J]. Cancer Cell Int, 2016, 16: 1-11.
    [42]
    SHAKER F, RAZI S, REZAEI N. Circulating miRNA and circulating tumor DNA application as liquid biopsy markers in gastric cancer[J]. Clin Biochem, 2024, 129: 110767. DOI: 10.1016/j.clinbiochem.2024.110767.
    [43]
    LIU L, LI P, WANG Q, et al. Diagnosis accuracy of the miR-200 family tumor marker series in ovarian cancer: a systematic review and meta-analysis[J]. Transl Cancer Res, 2022, 11(7): 2283-2290. doi: 10.21037/tcr-22-864
    [44]
    GUAN W, CUI H, HUANG P, et al. miR-200b/200a/429 cluster stimulates ovarian cancer development by targeting ING5[J]. J Oncol, 2020, 2020(1)3404059. DOI: 10.1155/2020/3404059.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (10) PDF downloads(0) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return